Theravance THRX

  1. All
  2. Commentary
  3. Stock Reports
  4. ETF Reports
  5. Headlines
    1. IBB iShares Nasdaq Biotechnology ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Wed, 16 Apr 2014

      21.5% of assets are invested in small- and mid-cap pharmaceutical firms such as Mylan MYL, Salix SLXP, and Theravance THRX ; the U.S.' largest pharmaceutical firms trade on the New York Stock Exchange. IBB's index is one of eight

    2. Theravance Is A Classic Ben Graham Bargain


      Fri, 4 Apr 2014

      Retiree : Within a few weeks Theravance ( THRX ) will split into two distinct ..... all other programs the current Theravance is developing. Biopharma will ..... all, let's take a look at Theravance 's likely future. How much

    3. Theravance : Baby Thrown Out With The Bath Water - 35% To 65% Upside


      Mon, 31 Mar 2014

      By KL Investment Partners : Theravance ( THRX ) is a biopharmaceutical company focused on the discovery ..... under agreements with GSK, which will pay annual royalties to Theravance . Unless stated otherwise, information is from the 10-K

    4. Theravance's CEO Presents at Barclays Global Healthcare Conference (Transcript)


      Tue, 11 Mar 2014

      Theravance , Inc. ( THRX ) JKLM Conference Call March 11, 2014 10:15 AM ET Executives ..... pleased to have our next presenting biotech company which is Theravance . And Theravance has made a lot of progress recently in terms of regulatory

    5. FDA panel votes in favor of approval of Glaxo lung drug Anoro


      Tue, 10 Sep 2013

      WASHINGTON, Sept 10 (Reuters) - An federal advisory panel has recommended that the U.S. Food and Drug Administration approve a drug made by GlaxoSmithKline Plc and Theravance Inc to treat chronic...

    6. Safety data on Glaxo COPD drug inconclusive -FDA staff


      Fri, 6 Sep 2013

      Sept 6 (Reuters) - An experimental drug to treat chronic obstructive pulmonary disease made by GlaxoSmithKline Plc and Theravance Inc appears to work, but its safety data are not entirely conclusive,...

    7. Elan Transformation Continues, but We Remain Skeptical of Deal Values


      Mon, 20 May 2013

      proposed new business deals, and we're maintaining our fair value estimate as we digest the news in relation to last week's Theravance deal announcement. We're intrigued by Elan's decision to take a page out of Valeant's playbook, focusing on underpenetrated

    8. The Benefits of Diversifying the Funding of a Gold Position


      Fri, 17 May 2013

      Theravance THRX reported second-quarter earnings that matched our expectations, and we are keeping our fair value estimate at $29 per share

    9. Elan's Theravance Deal Creates Passive Stake in Respiratory Disease; We Await Additional Deals


      Mon, 13 May 2013

      Elan ELN has announced that it intends to pay $1 billion to Theravance for a 21% stake in its royalty stream from partner GlaxoSmithKline ..... The deal relates to four of the six programs included in Theravance 's 2002 LABA partnership with Glaxo: Relvar Ellipta/Breo

    10. UPDATE 3-US FDA approves Glaxo/ Theravance drug for COPD lung disease


      Fri, 10 May 2013

      * Drug will compete with AstraZeneca's Symbicort (Updates with FDA comment, side effects)

    « Prev12345Next »
    Content Partners